Irinotecan Accord (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a pro‑drug that is converted in the body to SN‑38, which binds to the DNA‑topoisomerase I enzyme. By stabilising the enzyme‑DNA complex, SN‑38 prevents the re‑ligation of single‑strand DNA breaks during replication, leading to accumulation of DNA damage and tumour cell death.

The dose of Irinotecan Accord is determined individually by the prescribing oncologist based on factors such as the patient’s body surface area, disease stage, prior therapies, and organ function. No fixed dosing schedule is provided here; the prescriber sets the appropriate regimen.

Safety data for Irinotecan in pregnancy and lactation are limited. It is generally contraindicated unless the potential therapeutic benefit outweighs the possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the Irinotecan Accord product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, differing from agents such as oxaliplatin or 5‑fluorouracil that target DNA cross‑linking or thymidylate synthase. Its unique mechanism provides an alternative for patients who have progressed on other regimens, but it also carries distinct toxicity profiles, especially for diarrhea and neutropenia.

Irinotecan Accord should be stored at 2‑8 °C in a refrigerator, protected from light. The product must remain in its original packaging, should not be frozen or shaken, and must be handled using aseptic techniques to maintain sterility until administration.

The medication is supplied as a sterile solution for intravenous infusion. It is typically diluted in an appropriate carrier fluid and infused over a prescribed period, often ranging from 30 minutes to several hours, under close clinical monitoring for infusion‑related reactions.

The most critical adverse events include severe neutropenia with fever (febrile neutropenia), life‑threatening diarrhea that can progress to colitis or intestinal perforation, and hypersensitivity reactions such as anaphylaxis. Prompt recognition and management of these conditions are essential to reduce morbidity.

Patients with known hypersensitivity to irinotecan or any component of the formulation, those with uncontrolled infections, severe bone‑marrow suppression, or significant hepatic impairment should not receive the drug. Additionally, it is avoided in individuals for whom the risk‑benefit balance is unfavorable, such as certain pregnant women.